Levetiracetam as a possible cause of secondary graft failure after allogenic hematopoietic stem cell transplantation

Peyrl, Andreas; Weichert, Nina; Kühl, Jörn‐Sven; Ebell, Wolfram; Driever, Pablo Hernáiz

doi:10.1016/j.ejpn.2014.10.004

Cited by 8 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although EEG anomalies after HSCT are more common in patients treated with busulfan and levetiracetam for prophylaxis, we believe that the latter drug prevents the development of seizures. However, one study suggested that secondary transplantation failure was seen in patients treated with levetiracetam and that this failure may be related to myelodysplastic syndrome due to levetiracetam use 20 .…”

Section: Discussionmentioning

confidence: 99%

Evaluation of pre- and post-transplant electroencephalographic examination in hematopoietic stem cell transplant patients

Yavlal¹,

Güngen²,

Aras³

et al. 2023

Ideggyógyászati szemle

View full text Add to dashboard Cite

Background and purpose – Haematopoietic stem cell transplantation (HSCT) is one of the most effective treatment methods for many malignant and non-malignant diseases. In this study, we aimed to detect electroencephalographic (EEG) anomalies at an early stage in patients who underwent allogeneic and autologous HSCT and required the management of potentially lifethreatening non-convulsive seizures. Methods – The study was conducted with 53 patients. The age, gender, HSCT type (allogeneic or autologous), and treatment regimens applied before and after HSCT were recorded. All patients underwent EEG monitoring twice, once on the first day of hospitalization and again one week after conditioning regimens began and HSCT was performed. Results – When the pre-transplant EEG findings were examined, 34 (64.2%) patients had normal EEGs and 19 (35.8%) had abnormal EEGs. After transplantation, 27 (50.9%) had normal EEG findings, 16 (30.2%) had a basic activity disorder, 6 (11.3%) had a focal anomaly, and 4 (7.5%) had a generalised anomaly. In the allogeneic group, the anomaly rate in post-transplant EEGs was significantly higher than that in the autologous group (p<0.05). Conclusion – It is important to consider the likelihood of epileptic seizures in the clinical follow-up of HSCT patients. EEG monitoring is crucial for the early diagnosis and treatment of such non-convulsive clinical manifestations.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of pre- and post-transplant electroencephalographic examination in hematopoietic stem cell transplant patients

Yavlal¹,

Güngen²,

Aras³

et al. 2023

Ideggyógyászati szemle

View full text Add to dashboard Cite

show abstract

“…As mentioned above, levetiracetam is the first choice to semeiologically treat concurrent seizures after transplantation because of its favorable features. Surprisingly, Peyrl et al (105) reported a case of secondary graft failure after HSCT because of treatment-related myelodysplastic syndrome during the period of levetiracetam administration, and believed that levetiracetam was the possible cause. Therefore, studies on the safety profile of levetiracetam remain to be evaluated further in post-transplanted patients with seizure attacks.…”

Section: Pharmacological Therapymentioning

confidence: 99%

Epileptic Seizures After Allogeneic Hematopoietic Stem Cell Transplantation

2021

View full text Add to dashboard Cite

Technique in allogeneic hematopoietic stem cell transplantation has greatly advanced over the past decades, which has led to an increase in the number of patients receiving transplantation, but the complex procedure places these transplant recipients at high risk of a large spectrum of complications including neurologic involvement. As a common manifestation of neurological disorders, epileptic seizures after transplantation have been of great concern to clinicians because it seriously affects the survival rate and living quality of those recipients. The aim of this review is to elucidate the incidence of seizures after allogeneic hematopoietic stem cell transplantation, and to further summarize in detail its etiologies, possible mechanisms, clinical manifestations, therapeutic schedule, and prognosis, hoping to improve doctors' understandings of concurrent seizures following transplantation, so they can prevent, process, and eventually improve the survival and outlook for patients in a timely manner and correctly.

show abstract

“…Similarly, Cordelli et al [9] recommended the use of benzodiazepines as the first line of therapy in children, and using propofol in patients with refractory SE. A study reported that patients experience secondary transplantation failure after using levetiracetam, and this failure may be related to myelodysplastic syndrome induced by levetiracetam [85]. In the future, there should be more studies that aim to confirm the safety of recipients of hematopoietic stem cell transplantation using levetiracetam, and we should use AEDs that have fewer effects on bone marrow.…”

Section: Anti-epileptic Treatmentmentioning

confidence: 99%